Intelligence · Clinical Development
Pipeline search results
Programs matching “oncology” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 189 pipeline programs matching "oncology" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Infigratinib 0.25 mg/kg/day
BridgeBio Oncology Therapeutics
Achondroplasia
1 trial -
Intravenous Methylprednisolone
Cardiff Oncology
Myelitis, Transverse
1 trial -
KO-MEN-017
Kura Oncology
NPM1-m and KMT2A-r Acute Myeloid Leukemia
1 trial -
Mycophenolate Mofetil
Cardiff Oncology
Immune Thrombocytopenia
1 trial -
Oral triiodothyronine
Cardiff Oncology
Postoperative; Dysfunction Following Cardiac Surgery
1 trial -
P.64Cu.003.01
A.C.O.M. - Advanced Center Oncology
Prostate cancer at risk of developing metastatic lesions
1 trial -
Tetronine
Cardiff Oncology
Postoperative; Dysfunction Following Cardiac Surgery
1 trial -
Ziftomenib
Kura Oncology
Acute Myeloid Leukemia (AML)
1 trial -
infigratinib 0.128 mg/kg/day
BridgeBio Oncology Therapeutics
Hypochondroplasia
1 trial -
mesalazine (Asacol®)
Cardiff Oncology
Ulcerative Colitis
1 trial -
AG10
BridgeBio Oncology Therapeutics
Familial ATTR-CM (ATTRm-CM, or FAC)
1 trial -
AG10
BridgeBio Oncology Therapeutics
Amyloid Cardiomyopathy
1 trial -
APX005M
Pyxis Oncology
Melanoma
1 trial -
AT148009
ALX ONCOLOGY HOLDINGS INC
Breast Cancer
1 trial -
AZACITIDINE
ALX ONCOLOGY HOLDINGS INC
Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease
1 trial -
AZD5363
Cardiff Oncology
Estrogen Receptor Positive Breast Cancer
1 trial -
Aspirin
Cardiff Oncology
Venous Leg Ulcer
1 trial -
BGJ398 (infigratinib)
BridgeBio Oncology Therapeutics
Advanced Cholangiocarcinoma
1 trial -
CA126-0015
Bristol-Myers Squibb Australia Pty Ltd
Oncology, NSCLC and CRC
1 trial -
CG0070
CG Oncology
Non Muscle Invasive Bladder Cancer
1 trial -
CG0070
CG Oncology
Bladder Cancer
1 trial -
Casdozokitug
Coherus Oncology
Hepatocellular Carcinoma
1 trial -
Colonoscopy with enhanced dye
Cardiff Oncology
Colorectal Cancer
1 trial -
Cretostimogene Grenadenorepvec
CG Oncology
High-Risk Non-Muscle-Invasive Bladder Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.